A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
Latest Information Update: 04 Nov 2021
At a glance
- Drugs S 588210 (Primary)
- Indications Malignant-mesothelioma
- Focus Pharmacodynamics
Most Recent Events
- 07 Feb 2019 New trial record